Ytterbium in PDB 3ftu: Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol

All present enzymatic activity of Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol:
3.3.2.6;

The structure of Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol, PDB code: 3ftu was solved by D.R.Davies, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	50.00 / 1.90
Space group	P 21 21 21
Cell size a, b, c (Å), α, β, γ (°)	77.662, 87.381, 98.472, 90.00, 90.00, 90.00
R / Rfree (%)	18.8 / 22.8

The structure of Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol also contains other interesting chemical elements:

Zinc

(Zn)

1 atom

The binding sites of Ytterbium atom in the Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol (pdb code 3ftu). This binding sites where shown within 5.0 Angstroms radius around Ytterbium atom.
In total only one binding site of Ytterbium was determined in the Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol, PDB code: 3ftu:

Ytterbium binding site 1 out of 1 in the Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol


Mono view


Stereo pair view

A full contact list of Ytterbium with other atoms in the Yb binding site number 1 of Leukotriene A4 Hydrolase in Complex with Dihydroresveratrol within 5.0Å range: probe atom residue distance (Å) B Occ A:Yb702 b:29.2 occ:1.00 OXT A:ACT801 2.3 26.5 1.0 OD1 A:ASP481 2.4 24.6 1.0 OD2 A:ASP481 2.4 22.0 1.0 O A:HOH841 2.6 25.8 1.0 O A:HOH628 2.6 16.6 1.0 O A:ACT801 2.7 25.7 1.0 CG A:ASP481 2.7 25.0 1.0 C A:ACT801 2.8 26.9 1.0 O A:HOH842 3.2 27.0 1.0 CH3 A:ACT801 4.2 25.0 1.0 CB A:ASP481 4.3 23.7 1.0 OD2 A:ASP482 4.4 20.2 1.0 O A:HOH671 4.5 19.8 1.0 OD1 A:ASP482 4.5 22.5 1.0 CG A:ASP482 4.7 23.7 1.0 CB A:LYS479 4.8 19.8 1.0

D.R.Davies, B.Mamat, O.T.Magnusson, J.Christensen, M.H.Haraldsson, R.Mishra, B.Pease, E.Hansen, J.Singh, D.Zembower, H.Kim, A.S.Kiselyov, A.B.Burgin, M.E.Gurney, L.J.Stewart. Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography. J.Med.Chem. V. 52 4694 2009.
ISSN: ISSN 0022-2623
PubMed: 19618939
DOI: 10.1021/JM900259H